Skip to main content
Unchecking box will stop auto data updates
TSX Real-Time Last Sale CAD
Today's Change
Volume
Price Quote as of

Today's Trading

Day Low 2.88
Day High 2.96
Open:2.96
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

More stories below advertisement

Description
Resverlogix Corp clinical stage biotechnology company. Resverlogix is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Fundamentals

Market Capitalization, $M
Shares Outstanding, M
36-Month Beta
Earnings Per Share (TTM)
Revenue Growth YoY
Profit Margin
5-Year Avg. Revenue Growth
5-Year Avg. Profit Growth
1-Year Total Return
3-Year Total Return
5-Year Total Return
Price/Earnings (TTM)
Price/Earnings (Forward)
Trailing Annual Dividend & Yield
Forward Annual Dividend & Yield
Most Recent Dividend
Ex-Div Date
Most Recent Split
Return on Common Equity
Return-on-Assets (Before Tax)
Debt-to-Equity Ratio
Price/Book

Earnings

Corporate earnings are provided from Morningstar, including Income Statements,Balance Sheets, Cash Flow Statements, and Statement of Retained Earnings.

Analyst Research

Analyst Ratings and Earnings Estimates are provided by Zacks Investment Research – including Buy/Hold Recommendations, Earnings Surprises, Estimates and Recommendations History.

Stock Reports +

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

StockCalc Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

ValuEngine Reports

Download a comprehensive report detailing quantitative analytics of this equity. For subscribers only.

Latest Press Releases

Resverlogix Announces Publication on Apabetalone in Clinical Epigenetics
GlobeNewswire - Mon Jul 15, 7:30AM CDT
GlobeNewswire - CMTX
Mon Jul 15, 7:30AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced today the recent publication of an article titled: "Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism" in Clinical Epigenetics, a top tier, open access journal devoted to the study of epigenetic principles and mechanisms as applied to human development, disease, diagnosis and treatment.
Resverlogix's BETonMACE Phase 3 Epigenetics Trial Completes Final Safety Visits
GlobeNewswire - Mon Jul 8, 7:30AM CDT
GlobeNewswire - CMTX
Mon Jul 8, 7:30AM CDT
Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) is pleased to announce today that all patients active in BETonMACE, the Company's event-based, phase 3 registration trial, recently completed their final, follow-up safety visits, marking another important step towards trial completion. Given the remaining steps required to finalize BETonMACE (see below), the Company anticipates being in a position to provide top-line results in September 2019.
Zenith Epigenetics Announces Dosing of First Patient in Triple Negative Breast Cancer Trial with Pfizer
GlobeNewswire - Thu Jun 27, 7:30AM CDT
GlobeNewswire - CMTX
Thu Jun 27, 7:30AM CDT
Zenith Epigenetics Ltd. ("Zenith" or the "Company"), a wholly-owned subsidiary of Zenith Capital Corp., announced today that it has dosed the first patient in a Phase 1b/2 clinical trial undertaken in collaboration with Pfizer Inc. ("Pfizer"). The trial will evaluate the combination, safety and efficacy of the Company's ZEN-3694, a novel and differentiated bromodomain and extra-terminal domain inhibitor ("BETi"), and Pfizer's talazoparib, a poly ADP ribose polymerase inhibitor ("PARPi"), in patients with locally advanced or metastatic triple negative breast cancer without germline BRCA1/2 mutations.
Price History Describes more index sector components

Price Performance

Period Period Low Period High Performance
1-Month 2.63 +12.17% increase
on 06/25/19
Period Open:2.73
Price movement based on the high, low and last over the given period.
3.25 -9.23% decrease
on 07/03/19
+0.22 (+8.06%) increase
since 06/21/19
3-Month 2.62 +12.60% increase
on 06/21/19
Period Open:4.15
Price movement based on the high, low and last over the given period.
4.94 -40.28% decrease
on 05/08/19
-1.20 (-28.92%) decrease
since 04/23/19
52-Week 2.40 +22.92% increase
on 07/24/18
Period Open:2.43
Price movement based on the high, low and last over the given period.
4.94 -40.28% decrease
on 05/08/19
+0.52 (+21.40%) increase
since 07/23/18

More stories below advertisement

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2019.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).